Early PSA Change after [(177)Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival

por Kind, Felix, Fassbender, Thomas F., Andrieux, Geoffroy, Boerries, Melanie, Meyer, Philipp T., Ruf, Juri
Publicado 2021

Bone marrow impairment during early [(177)Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?

por Kind, Felix, Michalski, Kerstin, Yousefzadeh-Nowshahr, Elham, Meyer, Philipp T., Mix, Michael, Ruf, Juri
Publicado 2022